Q-omics provides the consensus-scored HSD17B14 profile across patient tissues and cancer cell-line models. HSD17B14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HSD17B14 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HSD17B14 RNA expression shows 14,059 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where HSD17B14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD17B14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD17B14 survival associations across molecular data types. HSD17B14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD17B14 RNA expression–survival associations across cancer types. High HSD17B14 expression shows unfavorable associations in UVM and UCEC, but favorable associations in HNSC, LUAD, SARC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for HSD17B14 RNA expression.
This table summarizes HSD17B14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSD17B14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD17B14 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, BRCA and STAD. The KIRC box plot shows higher HSD17B14 RNA expression in tumor versus normal tissue (log2 FC = +1.303, t-test p < 0.001).
This table shows molecular features associated with HSD17B14 in patient tissues and cancer cell lines. In patient samples, HSD17B14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HSD17B14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
